Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Ramona Hilgenkamp

Yan Lou

Francisco Javier Lopez-Tapia

Christine E Brotherton-Pleiss

Fariborz Firooznia

Timothy D Owens

Peter Michael Wovkulich

Roland Joseph Billedeau

Buelent Kocer

Steven Joseph Berthel

Saul Jaime-Figueroa

Stephen Deems Gabriel

Jenny Tan

Xiaochun Han

Lucja Orzechowski

Rama K Kondru

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Growing community of inventors

Montclair, NJ, United States of America

Ramona Hilgenkamp